Propanc Biopharma, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Propanc Biopharma, Inc. on October 21, 2021, regarding events occurring on that date. The Company, incorporated in Delaware with principal offices in Australia, entered into a material definitive agreement to secure financing.
Key Financial Metrics and Transaction Details
- Debt Instrument: Convertible Promissory Note with a principal amount of $63,750.
- Net Proceeds: $60,000 (after deducting $3,750 in fees and expenses).
- Interest Rate: 8% per annum, payable in cash or shares of common stock upon maturity or acceleration.
- Maturity Date: October 21, 2022.
- Conversion Terms: Convertible at the investor's option starting April 19, 2022, at a price equal to 65% of the Market Price (a 35% discount).
- Prepayment Penalties: Significant premiums apply for early repayment, ranging from 110% to 129% of the face amount plus accrued interest depending on the timing of prepayment.
- Default Penalty: Upon certain events of default, the obligation increases to 150% of the outstanding principal plus accrued interest.
Material Changes and Agreements
The primary material change is the creation of a direct financial obligation through the issuance of the Note to Sixth Street Lending, LLC. The transaction closed on October 26, 2021. The Company covenants not to sell substantially all assets without consent, which would render it a "shell company." The Note includes a 4.99% beneficial ownership limitation on conversion to prevent the investor from exceeding this threshold.
Outlook, Risks, and Contingencies
Use of Proceeds: The Company intends to use the net proceeds for general working capital purposes.
Risks and Contingencies:
- Dilution Risk: The 35% discount on the conversion price and the potential for interest to be paid in shares may result in significant dilution to existing shareholders.
- Liquidity Risk: The Company faces substantial prepayment penalties if it attempts to refinance or repay the debt early.
- Default Risk: Failure to deliver shares within three business days of a conversion notice incurs a $1,000 per day penalty. Certain defaults trigger an immediate acceleration of the debt at 150% of the principal.
- Reporting Requirements: The Company must maintain its listing on an OTC market or equivalent exchange and comply with SEC reporting requirements to avoid default.
Investor Verification Checklist
- Verify the Company's current cash position and ability to service the 8% interest or convert it to equity without immediate cash outflow.
- Review the Company's recent stock trading volume and price to assess the potential dilution impact of the 35% conversion discount.
- Confirm the Company's compliance status with SEC reporting requirements to avoid triggering the default clause related to reporting failures.
- Assess the likelihood of the Company needing to prepay the note within the first 180 days, given the escalating prepayment premiums.
- Check for any subsequent filings regarding the actual issuance of shares upon conversion or any amendments to the Note terms.